Adaptimmune

Adaptimmune and TCR2 Agree Merger

Clinical stage biotechs Adaptimmune and TCR2 Therapeutics have agreed to merge, forming what they said would be a “preeminent cell therapy company focused on creating solid tumors” with projected sales of about $27 billion by 2026.

News

Adaptimmune Strengthens Management Team with Key Executive Hires

News

Adaptimmune in Cancer Collaboration With GlaxoSmithKline

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Industry Kick-Off with Signal Effect: More Than 310 Exhibitors expected at maintenance and PUMPS & VALVES 2026

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

JMP Statistical Discovery / SAS Institute GmbH

From Data to Decisions: Digital Tools Reshaping the Chemical and Life Sciences Landscape

Brenntag SE

Brenntag Downsizes Management Board, Retains Both Divisions

Easyfairs Deutschland GmbH

Leading the way. Driving results.

WuXi AppTec

Europe’s Biotech Inflection Point

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Adaptimmune

Adaptimmune and TCR2 Agree Merger

Adaptimmune Strengthens Management Team with Key Executive Hires

Adaptimmune in Cancer Collaboration With GlaxoSmithKline

Top-Feature

API Manufacturing

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Anchored in Sustainability

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Leading Transformation